Using Optical Coherence Tomography to assess Uveitis
Objective Grading of Intraocular Inflammation in Uveitis Using Optical Coherence Tomography
This study is testing how Optical Coherence Tomography can help doctors better understand and measure the severity of uveitis by looking at inflammatory cells in the eye.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 75 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Oregon Health and Science University Academic / other |
| Locations | 1 site (Portland, Oregon) |
| Trial ID | NCT02026128 on ClinicalTrials.gov |
What this trial studies
This observational study utilizes Optical Coherence Tomography (OCT) to evaluate the severity of uveitis by measuring the presence of inflammatory cells in the anterior chamber of the eye. The study aims to standardize the grading of these cells and investigate differences in cell size and protein concentration across various uveitis diagnostic categories. Participants will undergo OCT testing alongside standard assessments like visual acuity and slit lamp exams to determine their eligibility based on specific clinical features of uveitis. Background data on participants' demographics and medical history will also be collected to support the findings.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with specific clinical features indicative of uveitis.
Not a fit: Patients unable to provide informed consent or maintain stable fixation for OCT imaging may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy and management of uveitis, enhancing patient outcomes.
How similar studies have performed: While the use of OCT in uveitis is a growing area of interest, this specific approach to standardizing cell grading is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age and older * With one or more of the following clinical features: 1. \>1+ AC cells; 2. \>1+ vitreous haze; 3. presence of vitreous cells; 4. presence of blood in anterior chamber; 5. presence of blood in vitreous; 6. presence of aqueous or vitreous pigment. * In one of the following diagnostic categories as determined by a uveitis specialists: 1. uveitis due to ankylosing spondylitis (positive HLA B27 genotype); 2. uveitis due to sarcoidosis; 3. uveitis of any additional type; 4. uveitis masquerade such as pigment dispersion syndrome or Schaffer's sign; 5. hyphema due to trauma or other causes; 6. vitreous hemorrhage; 7. retinal tear. Exclusion Criteria: * Inability to give informed consent; * Inability to maintain stable fixation for OCT imaging.
Where this trial is running
Portland, Oregon
- Oregon Health & Science University — Portland, Oregon, United States (Recruiting)
Study contacts
- Principal investigator: David Huang, MD, PhD — Oregon Health and Science University
- Study coordinator: Denny Romfh, OD
- Email: romfhd@ohsu.edu
- Phone: 503-494-4351
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.